This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert Baran, MD
Department of Dermatology Cannes General Hospital 06407 Cannes, France

Arch Dermatol. 1984;120(8):993.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The letter to the editor by Rabinovitz et al¹ on the therapeutic benefits from etretinate in two cases of psoriatic nails prompted me to report my previous experience. In 1981, I published a therapeutic assessment of etretinate and its side effects based on a series of 96 patients.²

The therapeutic response was disappointing in almost all of our cases. This was due to the severe reduction in the rate of nail growth (in 55 patients) and the drug-induced modifications, which involved all epidermal structures of the nail apparatus. Side effects included nail fragility in 60 patients, onychomadesis in nine patients, paronychia in four patients, complete nail loss in two patients, and onycholysis in one patient. Nail fragility may occur in isolation or it may accompany any of the other anomalies. In addition, I have recently seen a patient with transverse leukonychia involving all of the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?